Constance Keyserling
Directeur des opérations chez ABIONYX PHARMA
Postes actifs de Constance Keyserling
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ABIONYX PHARMA | Directeur des opérations | - | - |
| Corporate Officer/Principal | - | - |
Historique de carrière de Constance Keyserling
Anciens postes connus de Constance Keyserling
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
| ESPERION THERAPEUTICS, INC. | Directeur des opérations | - | - |
| Parke, Davis & Co. LLC | Corporate Officer/Principal | - | - |
QuatRx Pharmaceuticals Co.
 QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - | - |
Formation de Constance Keyserling
| Harvard University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| France | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Chief Operating Officer | 2 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ABIONYX PHARMA | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
| Parke, Davis & Co. LLC |
- Bourse
- Insiders
- Constance Keyserling
- Expérience
